Basic Information
Spravato
Regulatory Information
EMEA/H/C/004535
Authorised
December 18, 2019
October 17, 2019
15
September 4, 2024
Company Information
Belgium
Turnhoutseweg 30 B-2340 Beerse
Janssen-Cilag International NV
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.
Overview Summary
Spravato is a medicine used to treat adults with major depression that is resistant to treatment. It is used in combination with an SSRI or SNRI medicine (other antidepressants) when at least two other treatments have failed. Spravato contains the active substance esketamine.